Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginkgo ketoester (also known as GBE50) is a standardized, fifth-generation extract of *Ginkgo biloba* leaves containing at least 44% total flavonoids (including flavonol glycosides) and at least 6% terpene lactones (including ginkgolides and bilobalide), with toxic ginkgolic acids restricted to below 5 ppm. It acts primarily as an antagonist of the platelet-activating factor (PAF) receptor, which inhibits platelet aggregation, reduces blood viscosity, and improves microcirculation. Additionally, it exhibits potent antioxidant and neuroprotective properties by scavenging free radicals, enhancing superoxide dismutase (SOD) and glutathione (GSH) levels, and suppressing neuroinflammatory pathways. Ginkgo ketoester is developed and marketed in China for the treatment of cardiovascular and cerebrovascular diseases, including coronary heart disease, angina pectoris, and vertigo caused by cerebral arteriosclerosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginkgo ketoester.